New drug cocktail aims to stall deadly pancreatic cancer

NCT ID NCT04666740

Ongoing Disease control Sponsor: Memorial Sloan Kettering Cancer Center Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether combining two drugs, pembrolizumab and olaparib, can help people with a specific type of advanced pancreatic cancer keep their disease from growing. The trial includes 63 adults whose cancer has a genetic flaw called HRD or has responded well to platinum chemotherapy. The goal is to see if the combo works better than olaparib alone as a long-term maintenance treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HOMOLOGOUS RECOMBINATION DEFICIENCY (HRD) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

pancreatic acinar cell carcinoma pancreatic ductal adenocarcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HOMOLOGOUS RECOMBINATION DEFICIENCY (HRD) METASTATIC PANCREATIC DUCTAL ADENOCARCINOMA

Contacts and locations

Locations

Memorial Sloan Kettering Basking Ridge (All protocol activities)

New York, New York, 10065, United States
Memorial Sloan Kettering Bergen (All protocol activities)

Montvale, New Jersey, 07645, United States
Memorial Sloan Kettering Cancer Center

New York, New York, 10065, United States
Memorial Sloan Kettering Cancer Center @ Suffolk-Commack (All protocol activities)

Commack, New York, 11725, United States
Memorial Sloan Kettering Monmouth (All protocol activities)

Middletown, New Jersey, 07748, United States
Memorial Sloan Kettering Nassau (All protocol activities)

Rockville Centre, New York, 11553, United States
Memorial Sloan Kettering Westchester (All Protocol Activities)

Harrison, New York, 10604, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.